Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...

BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.

Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.

Becton, Dickinson and Company has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.

Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.

Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.

WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.

OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.

Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.

On August 6, Jim Cramer highlighted Becton, Dickinson and Company (NYSE:BDX) on CNBC’s Mad Money following its third-quarter fiscal 2026 financial report and said: This morning, we got a very strong quarter from BD. That’s the big medical technology and supply play… That was formerly known as Becton, Dickson. This was the first full quarter […]

Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where the dividend coverage story is quietly getting stronger.

Becton Dickinson has seen its analyst fair value estimate move from US$181.23 to US$189.58, signaling a refreshed price target framework that investors are watching closely. This shift reflects how recent research is weighing the solid fiscal Q3 beat, product updates, and mixed views on 2027 utilization and margin risk. As you read on, you will see how these moving pieces shape the evolving narrative around Becton Dickinson and what that could mean for your own assessment of the stock. Stay...

Becton, Dickinson and Company recently reported third-quarter fiscal 2026 results, with sales rising to US$4,983 million while net income fell to US$377 million, and modestly raised its full-year outlook for low single-digit plus GAAP revenue growth. Alongside these earnings, BD highlighted strong momentum in biologic drug delivery and GLP-1–related partnerships, including a new semaglutide pen collaboration with EMS in Brazil, underscoring the growing role of its Vystra Injection Pen...

BDX beats expectations with 4.4% FX-neutral revenue growth, raises full-year EPS guidance, and outlines strategic plans to navigate fiscal 2027 headwinds.

Becton, Dickinson and Company (NYSE:BDX) reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company’s expectations. Chairman, Chief Executive Officer and President Tom Po

Moby summary of Becton, Dickinson and Company's Q3 2026 earnings call

BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.

Becton Dickinson (BDX) raised its full-year earnings guidance as the medical device maker's third-qu

The headline numbers for Becton Dickinson (BDX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Becton Dickinson (BDX) delivered earnings and revenue surprises of +2.87% and +1.81%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

US equity markets were mostly pointing higher before the opening bell Thursday as investors assess p

BDX's Medical Essentials and Interventional strength may drive third-quarter fiscal 2026 results, but China, vaccines and projected declines weigh on expectations.

Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Waters Corporation (NYSE:WAT) reported second-quarter 2026 results that came in ahead of Wall Street expectations, supported by strong organic growth across its pharmaceutical and industrial businesses. The analytical instruments and diagnostics company’s shares were little changed in pre-market trading, edging up 0.

Henry Schein (HSIC) delivered earnings and revenue surprises of +4.10% and +2.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson stock has delivered a 20.9% one year return, yet the valuation checks send a mixed message, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market multiples look closer to fair. The 20.9% return over the past year suggests investors have already priced in some optimism, which raises the bar for any further upside to be supported by fundamentals. Growing use of data and AI tools across medical device companies, highlighted by...

They may profit from the rapidly growing GLP-1 market in very different ways.

Becton Dickinson (BDX) is back in focus after announcing a collaboration with EMS to support the launch of a semaglutide therapy in Brazil. The deal spotlights BD’s Vystra injection pen platform in chronic disease care. See our latest analysis for Becton Dickinson. Becton Dickinson’s recent EMS partnership and dividend affirmation come as the stock trades at US$166.34, with a 90-day share price return of 14.47% but a year-to-date share price decline of 14.67%. The 1-year total shareholder...

Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls

Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.

The chief investment strategist at Concurrent Asset Management shares her top investment picks right now.

A steadily shrinking share count and a giant float owed to suppliers are handing owners a bigger slice of the drug distributor each year, even as drug-pricing worries hang over the stock.

Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.

The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.

Becton, Dickinson and Company will release its third-quarter earnings next month, and analysts anticipate a double-digit profit dip.

The S&P 500 index posted a total return of 9.9% from Jan. 2 through June 30. Here’s how our panelists’ picks did in that period.